ChrysCapital-backed Intas Pharma weighs $1-bn bid for Biogen's biosimilars biz
Advertisement

ChrysCapital-backed Intas Pharma weighs $1-bn bid for Biogen's biosimilars biz

By Ranjani Raghavan

  • 13 Sep 2023
Premium
ChrysCapital-backed Intas Pharma weighs $1-bn bid for Biogen's biosimilars biz

Intas Pharmaceuticals Ltd is preparing a bid for Biogen Inc.’s biosimilar business in a transaction that could be valued at as much as $1 billion, two people familiar with the talks said. Ahmedabad-based Intas is being advised by Goldman Sachs Group Inc., one of the people said, adding that the company ......

This is a Premium article. Please subscribe or log in to read the full story!

Here's a selection of our recent premium content.

Already a member? Click here to log in.
Advertisement
Advertisement
Google News Icon

Google News

Follow VCCircle on Google News for the latest updates on Business and Startup News